Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia

NCT05832216 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Aplastic Anemia
Platelet Transfusion Refractoriness

Interventions

DRUG: Daratumumab

Sponsor

Institute of Hematology & Blood Diseases Hospital, China